CNS Pharmaceuticals Inc

CNS Pharmaceuticals maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $8.62 million against total liabilities of $4.10 million, leaving total equity of $4.52 million. Liquidity is supported by cash and equivalents of $7.20 million, which exceeds total liabilities, providing a buffer against near-term solvency concerns despite the low liquidity risk rating. The market capitalization stands at $3.22 million, implying a price-to-book ratio of 0.71, suggesting the market values the company below its tangible book value.

Profitability metrics reflect the pre-commercial or early-stage nature of the business, with a net income loss of $15.85 million and an operating income loss of $15.99 million. Return on equity is negative at -3.50, and return on assets is -1.84, indicating that current operations are consuming capital rather than generating returns. The EV/EBITDA ratio of 0.25 is a distorted metric due to negative earnings, rendering traditional valuation multiples less meaningful for peer comparison. Without cohort median data provided, direct profitability comparisons are omitted, but the negative returns are consistent with biopharma firms in clinical development phases.

Segment and geographic revenue data are not disclosed in the available input, preventing an analysis of revenue concentration or geographic exposure. The absence of segment breakdown suggests the company may not yet have significant commercial revenue streams to report by product line or region.

Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot shows a significant cash burn, with operating cash flow at -$13.81 million, while capital expenditures remain minimal at $18,175. This pattern indicates that cash outflows are primarily driven by operating expenses such as research and development or general administrative costs rather than asset acquisition.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company has 632,516 basic and diluted shares outstanding, with no difference between basic and diluted counts, suggesting no current options or convertible securities are impacting the share count. The primary risk remains the operational burn rate against the cash balance; with $7.20 million in cash and a recent operating cash outflow of $13.81 million, the runway is limited unless cash burn decelerates or new capital is raised.

Recent observations include analyst estimates with a mean, median, high, and low price target of $10.00, representing a significant upside from the current market price of $5.09. The mean recommendation is 2.00 (Buy), driven by one Buy rating and no Hold or Strong Buy ratings. This analyst sentiment suggests expectations for positive catalysts, such as clinical trial results or partnership announcements, that are not yet reflected in the current financial performance.

Operating income −14,7% YoY; Net income −14,8% YoY.

• ▍Operating income −14,7% YoY
• ▍Net income −14,8% YoY
• ▍Free cash flow −14,9% YoY

Operating income −87,1% YoY; Net income −87,5% YoY.

• ▍Operating income −87,1% YoY
• ▍Net income −87,5% YoY
• ▍Free cash flow −87,3% YoY

Operating income +42,2% YoY; Net income +42,6% YoY.

• ▍Operating income +42,2% YoY
• ▍Net income +42,6% YoY
• ▍Free cash flow +42,6% YoY

Operating income -$3.2M.

• ▍Operating income -$3.2M

Operating income −7,3% YoY; Net income −6,7% YoY.

• ▍Operating income −7,3% YoY
• ▍Net income −6,7% YoY
• ▍Free cash flow −6,8% YoY

Operating income +21,0% YoY; Net income +21,2% YoY.

• ▍Operating income +21,0% YoY
• ▍Net income +21,2% YoY
• ▍Free cash flow +21,2% YoY

Operating income −5,4% YoY; Net income −5,4% YoY.

• ▍Operating income −5,4% YoY
• ▍Net income −5,4% YoY
• ▍Free cash flow −5,4% YoY

Operating income -$14.5M.

• ▍Operating income -$14.5M